These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36604563)

  • 21. Genetic analysis of 62 Chinese families with Duchenne muscular dystrophy and strategies of prenatal diagnosis in a single center.
    Zhang J; Ma D; Liu G; Wang Y; Liu A; Li L; Luo C; Hu P; Xu Z
    BMC Med Genet; 2019 Nov; 20(1):180. PubMed ID: 31727011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China.
    Wang DN; Wang ZQ; Yan L; He J; Lin MT; Chen WJ; Wang N
    Neuromuscul Disord; 2017 Aug; 27(8):715-722. PubMed ID: 28318817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations Between Self-Reported Behavioral and Learning Concerns and DMD Isoforms in Duchenne Muscular Dystrophy.
    Counterman KJ; Fatovic K; Good DC; Martin AS; Dasgupta S; Anziska Y
    J Neuromuscul Dis; 2022; 9(6):757-764. PubMed ID: 36245385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences.
    Vry J; Gramsch K; Rodger S; Thompson R; Steffensen BF; Rahbek J; Doerken S; Tassoni A; Beytía ML; Guergueltcheva V; Chamova T; Tournev I; Kostera-Pruszczyk A; Kaminska A; Lusakowska A; Mrazova L; Pavlovska L; Strenkova J; Vondráček P; Garami M; Karcagi V; Herczegfalvi Á; Bushby K; Lochmüller H; Kirschner J
    J Neuromuscul Dis; 2016 Nov; 3(4):517-527. PubMed ID: 27911335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of β
    Kelley EF; Cross TJ; Snyder EM; McDonald CM; ; Hoffman EP; Bello L
    Respir Res; 2019 Oct; 20(1):221. PubMed ID: 31619245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving recognition of Duchenne muscular dystrophy: a retrospective case note review.
    van Ruiten HJ; Straub V; Bushby K; Guglieri M
    Arch Dis Child; 2014 Dec; 99(12):1074-7. PubMed ID: 25187493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower Extremity Functional Outcome Measures in Duchenne Muscular Dystrophy-A Delphi Survey.
    Senesac CR; Lott DJ; Willcocks RJ; Duong T; Smith BK
    J Neuromuscul Dis; 2019; 6(1):75-83. PubMed ID: 30562905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan.
    Chien YH; Lee NC; Weng WC; Chen LC; Huang YH; Wu CS; Hwu WL
    Neurol Sci; 2022 Jul; 43(7):4563-4566. PubMed ID: 35562557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
    Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD
    J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnosis and treatment with steroids for patients with Duchenne muscular dystrophy: experience and recommendations for Mexico. Administración del Patrimonio de la Beneficencia Pública. Asociación de Distrofia Muscular de Occidente].
    Vázquez-Cárdenas NA; Ibarra-Hernández F; López-Hernández LB; Escobar-Cedillo RE; Ruano-Calderón LA; Gómez-Díaz B; García-Calderón N; Carriedo-Dávila MF; Rojas-Hurtado LG; Luna-Padrón E; Coral-Vázquez RM; ;
    Rev Neurol; 2013 Nov; 57(10):455-62. PubMed ID: 24203668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene Therapy for Duchenne Muscular Dystrophy: Unlocking the Opportunities in Countries in the Middle East and Beyond.
    Elbashir H; Fathalla W; Mundada V; Iqbal M; Al Tawari AA; Chandratre S; Bastaki L; Romany I; Ismayl O; Abou Tayoun A
    J Neuromuscul Dis; 2022; 9(6):787-801. PubMed ID: 36245386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS.
    Arpan I; Willcocks RJ; Forbes SC; Finkel RS; Lott DJ; Rooney WD; Triplett WT; Senesac CR; Daniels MJ; Byrne BJ; Finanger EL; Russman BS; Wang DJ; Tennekoon GI; Walter GA; Sweeney HL; Vandenborne K
    Neurology; 2014 Sep; 83(11):974-80. PubMed ID: 25098537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].
    Bernert G; Hahn A; Köhler C; Meyer S; Schara U; Schlachter K; Trollmann R; Walter MC
    Nervenarzt; 2021 Apr; 92(4):359-366. PubMed ID: 33215271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling disease trajectory in Duchenne muscular dystrophy.
    Rooney WD; Berlow YA; Triplett WT; Forbes SC; Willcocks RJ; Wang DJ; Arpan I; Arora H; Senesac C; Lott DJ; Tennekoon G; Finkel R; Russman BS; Finanger EL; Chakraborty S; O'Brien E; Moloney B; Barnard A; Sweeney HL; Daniels MJ; Walter GA; Vandenborne K
    Neurology; 2020 Apr; 94(15):e1622-e1633. PubMed ID: 32184340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A descriptive epidemiological study of Duchenne muscular dystrophy in childhood in Estonia.
    Talkop UA; Kahre T; Napa A; Talvik I; Sööt A; Piirsoo A; Sander V; Talvik T
    Eur J Paediatr Neurol; 2003; 7(5):221-6. PubMed ID: 14511626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duchenne Muscular Dystrophy in Kazakhstan: A Journey from Diagnosis to the Treatment, the Biases and Achievements.
    Jaxybayeva A; Chunkayeva D; Myrzaliyeva B; Ayaganov D; Lepessova M; Bulekbayeva S; Idrissova Z; Mukhambetova G; Bayanova M; Malfatti E; Urtizberea A
    J Neuromuscul Dis; 2023; 10(2):263-269. PubMed ID: 36641684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.